[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100583452":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":33,"centralContacts":37,"locations":45,"responsibleParty":64,"collaborators":66,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":10,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":80,"minAge":81,"maxAge":10,"enrollmentInfo":82,"targetDuration":10,"studyType":85,"phases":10,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":94,"whyStopped":10,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Hull University Teaching Hospitals NHS Trust","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Control Cohort",null,"* Participants routinely attending the Immunology and Allergy Clinical at Hull University Teaching Hospitals\n* Participants over the age of 18 years\n* Participants with no clinical and laboratory findings of IgE-mediated hypersensitivity (i.e. no clinical history of specific allergies to pollens, house dust mite or insect venoms, negative serological testing for specific IgE to pollens, house dust mite and insect venoms)",[13],"Diagnostic Test: Venepuncture",{"label":15,"type":10,"description":16,"interventionNames":17},"Test Cohort","1. Participants routinely attending the Immunology and Allergy Clinical at Hull University Teaching Hospitals\n2. Participants over the age of 18 years\n3. Participants with physician-diagnosed IgE-mediated allergic disease to pollens, house dust mite or insect venoms\n4. Participants who are eligible to commence allergen immunotherapy (AIT). AIT will comprise;\n\n   * Sublingual immunotherapy (SLIT) Grazax for grass pollen allergy or Acarizax for house dust mite allergy\n   * Subcutaneous immunotherapy (SCIT) Venom immunotherapy involving subcutaneous injections against bee or wasp venoms (as per schedule following conventional or modified rush protocols)\n\nAIT eligibility decided upon through combination of clinical assessment, multi-disciplinary team (MDT) meeting discussion and BSACI guidance.",[13,18],"Drug: Allergen Specific Immunotherapy",[20,25,30],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"DIAGNOSTIC_TEST","Venepuncture","Whole blood flow cytometry analysis of T-\u002FB-lymphocyte subsets, regulatory B cells and regulatory T cells. Serological detection (immunoassay) of allergen-specific IgE and IgG4",[9,15],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":10},"DRUG","Allergen Specific Immunotherapy","Test group receiving venom allergen immunotherapy as part of standard and routine care pathway (treatment commencement NOT for study purposes, cohort selected of those who are routinely commencing treatment).",[15],{"type":26,"name":27,"description":31,"armGroupLabels":32,"otherNames":10},"Test group receiving pollen allergen immunotherapy as part of standard and routine care pathway (treatment commencement NOT for study purposes, cohort selected of those who are routinely commencing treatment).",[15],[34],{"name":35,"affiliation":5,"role":36},"Kristina Emsell-Needham, BSc, MSc","PRINCIPAL_INVESTIGATOR",[38,42],{"name":35,"role":39,"phone":40,"phoneExt":10,"email":41},"CONTACT","+441482607813","Kristina.Emsell-Needham@nhs.net",{"name":43,"role":39,"phone":10,"phoneExt":10,"email":44},"Sujoy Khan, MD, MBBS, FRCPE","sujoy.Khan@nhs.net",[46],{"facility":47,"status":10,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Hull Teaching Hospital NHS Trust","Hull","East Yorkshire","HU3 2JZ","United Kingdom","UK",{"type":54,"coordinates":55},"Point",[56,57],-0.33525,53.7446,{"lat":57,"lon":56},[60,62,63],{"name":35,"role":39,"phone":61,"phoneExt":10,"email":41},"01482607813",{"name":43,"role":39,"phone":10,"phoneExt":10,"email":44},{"name":35,"role":36,"phone":10,"phoneExt":10,"email":10},{"type":65,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[67,70],{"name":68,"class":69},"Health Education England, Wessex","OTHER",{"name":71,"class":69},"University of Manchester","100583452","identification-of-b-regulatory-cells-by-flow-cytometry-100583452",false,"NCT06876506","Identification of B Regulatory Cells by Flow Cytometry","Identification and Quantitation of Human B Regulatory Cells Via Flow Cytometry and Their Potential Role as a Treatment Efficacy Biomarker in Allergen-specific Immunotherapy","Control cohort - Participants with:\n\n* No clinical and laboratory findings of IgE-mediated hypersensitivity (i.e. no clinical history of specific allergies to pollens, house dust mite or insect venoms\n* Negative serological testing for specific IgE to pollens, house dust mite and insect venoms\n* Patients aged 18 years or older\n\nTest cohort:\n\n* Participants over the age of 18 years\n* Participants with physician-diagnosed IgE-mediated allergic disease to pollens, house dust mite or insect venoms\n\nExclusion Criteria:\n\n* Patients under the age of 18 years\n* Samples from patients with IgE-mediated allergic disease, treated or untreated, specific to allergens other than pollens, house dust mite and insect venom\n* Participants who are pregnant\n* Participants who cannot adequately understand verbal and \u002F or written explanations given in English",true,"ALL","18 Years",{"count":83,"type":84},80,"ESTIMATED","OBSERVATIONAL","The goal of this laboratory and observational study is to develop a test to quantify B-regulatory cells in blood. This will be used to detect changes in B-regulatory cell populations in pollen and insect venom allergic patients who are receiving routine allergen immunotherapy treatment. The primary question this study aims to answer is;\n\n1). Are changes in blood B-regulatory cells associated with successful allergen immunotherapy treatment, and therefore do these changes suggest patients have developed a suitable level of allergen tolerance and reduction in their allergic symptoms upon re-exposure to the causal allergen.\n\nPatients will also be asked to complete quality of life questionnaire periodically throughout the study to determine if there are associations between variation in B-regulatory cell populations in blood and allergic symptoms experienced.",[88,89],"Pollen Allergy","Venom Allergy",[88,89,91,92,93],"Allergen Immunotherapy","B-regulatory cells","dust mite allergy","NOT_YET_RECRUITING","2026-06-22",{"date":97,"type":98},"2026-06-23","ACTUAL",{"date":100,"type":84},"2026-08-01",{"date":102,"type":84},"2027-09-30",{"name":5,"class":6},1]